In a pharmacoeconomic study, incremental cost-effectiveness ratio (ICER) is calculated as $80,000 per QALY. Using the commonly cited US willingness-to-pay threshold, how should this be classified?
-
A
Highly cost-effective
-
B
Borderline cost-effective
-
C
Not cost-effective
-
D
Dominant strategy